Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 8/12/2019
SIETES contiene 92850 citas

 
 
 1 a 20 de 91 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen

Se ha producido un error durante la generación de la página

. Drug-induced osteoporosis/osteomalacia: analysis in the French and Spanish pharmacovigilance databases. Eur J Clin Pharmacol 2019;75:diciembre. [Ref.ID 103213]
2. Cita con resumen
Anónimo. Troubles rétiniens d'origine médicamenteuse. Prescrire 2019;39:19-25. [Ref.ID 103005]
3.Enlace a cita original Cita con resumen
Hershman DL, Unger JM, Greenlee H, Capodice JL, Lew DL, Darke AK, Kengla AT, Melnik MK, Jorgensen CW, Kreisle WH, Minasian LM, Fisch MJ, Henry NL, Crew KD. Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer. A randomized clinical trial. JAMA 2018;319:10 de julio. [Ref.ID 102791]
4.Enlace a cita original Cita con resumen
Wang R, Kim BV, van Wely M, Johnson NP, Costello MF, Zhang H, Ng EHY, Legro RS, Bhattacharya S, Norman RJ, Mol BWJ. Treatment strategies for women with WHO group II anovulation: systematic review and network meta-analysis. BMJ 2017;356:j138. [Ref.ID 101407]
5. Cita con resumen
Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Diéras V, Slamon DJ. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016;375:17 de noviembre. [Ref.ID 100990]
6. Cita con resumen
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Balckwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobssen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy J. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 2016;375:1738-48. [Ref.ID 100961]
8. Cita con resumen
Anónimo. Anastrozole: syndromes du canal carpien. Prescrire 2016;36:426. [Ref.ID 100544]
9. Cita con resumen
Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon K, Whelan T, Strasser-Weippi K, Rubin S, Sturtz K, Wolff AC, Winer E, Hudis C, Stopeck A, Beck JT, Kaur JS, Whelan K, Tu D, Parulekar WR. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 2016;375:209-19. [Ref.ID 100399]
11.Enlace a cita originalTiene citas relacionadas
Mayer EL, Burstein HJ. Postmenopausal breast cancer: a best endocrine strategy?. Lancet 2015;386:1317-9. [Ref.ID 99617]
12. Cita con resumen
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015;386:1341-52. [Ref.ID 99276]
13. Cita con resumen
Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, Christman GM, Huang H, Yan Q, Alvero R, Haisenleder DJ, Barnhart KT, Bates GW, Usadi R, Lucidi S, Baker V, Trussell JC, Krawetz SA, Snyder P, Ohl D, Santoro N, Eisenberg E, Zhang H, for the NICHD Reproductive Medicine Network. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med 2014;371:119-29. [Ref.ID 97808]
14. Cita con resumen
16. Cita con resumen
Shah S. Novartis's fourth quarter bumps up 2008 results. Scrip 2009;3431:6. [Ref.ID 85226]
17. Cita con resumen
Sjöqvist F, Garle M, Rane A. Use of doping agents, particularly anabolic steroids, in sports and society. Lancet 2008;371:1872-82. [Ref.ID 83085]
Seleccionar todas
 
 1 a 20 de 91 siguiente >>